Development of rheumatoid arthritis refractory to conventional treatment
Keywords:
rheumatoid arthritis, antirheumatic, biological productsAbstract
Rheumatoid arthritis is a systemic chronic inflammatory disease that affects 0.4% to 1% of Latin America, manifested by chronic pain, joint destruction and premature death, affecting mainly women. Using the Health Assessment Questionnaire score, a count of swollen joints, presence of rheumatoid nodules, rheumatoid factor, erythrocyte sedimentation rate, C-reactive protein and erosions in radiography, were associated with the choice of the first treatment with disease-modifying antirheumatic drugs (DMARDs). To determine the main studies that ensure efficacy towards the development of rheumatoid arthritis refractory to conventional treatment. The literature search was carried out by means of an exploration of articles in PubMed and SciELO; Original and review articles were considered, published in English and Spanish, making use of the descriptors, a preliminary reading of the articles was carried out with the aim ofSelect those that fit our purpose, the documents that had information with the formal aspects, were included in our review, that is, a rigorous reading, which selected a total of 24 articles. It is at this point that clinical observation has made it possible to describe that not all patients have the same course of evolution of the disease, even with standardized treatments worldwide, and when evaluating the outcomes of the disease it is suggested that there must be characteristics of each patients who cause their disease to cause more damage in their evolution compared to other patients.
Downloads
References
Atsumi T, Yamamoto K, Takeuchi T, Yamanka H, Ishiguro N, Tanaka Y, et al. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. Annals of the Rheumatic Diseases. 2016[Acceso 06/05/2020];75(1):75-83. Disponible en: https://pubmed.ncbi.nlm.nih.gov/26139005/
Kumar LD, Karthik R, Gayathri N, Sivasudha T. Advancement in contemporary diagnostic and therapeutic approaches for rheumatoid arthritis. Biomed Pharmacother. 2016[Acceso 08/06/2020];79:52-61. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/27044812
Song X, Lin Q. Genomics, transcriptomics and proteomics to elucidate the pathogenesis of rheumatoid arthritis. Rheumatol Int. 2017[Acceso 16/07/2020];37(8):1257-1265. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/28493174
Aletaha D. Precision medicine and management of rheumatoid arthritis. J Autoimmun. 2020. doi: 10.1016/j.jaut.2020.102405. https://www.ncbi.nlm.nih.gov/pubmed/32276742
Mankia K, Di Matteo A, Emery P. Prevention and cure: The major unmet needs in the management of rheumatoid arthritis. J Autoimmun. 2020. [Acceso 25/06/2020]; Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/31899021
Verstappen SMM. The impact of socio-economic status in rheumatoid arthritis. Rheumatology(Oxford). 2017 [Acceso 21/06/2020];56(7):1051-2. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/27940587
Scherer H, Häupl T, Burmester GR. The etiology of rheumatoid arthritis. J Autoimmun. 2020. [Acceso 21/06/2020]; Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/31980337
Rais R, Saeed M, Haider R. Rheumatoid arthritis clinical features and management strategies at an urban tertiary facility in Pakistan. J Pak Med Assoc. 2014 [Acceso 21/06/2020]; 64(12):1435-7. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/25842598
Yamanaka H. Diagnosis and treatment of rheumatoid arthritis:toward the best practice. How to use the guideline in the management of rheumatoid arthritis. Clin Calcium. 2018 [Acceso 21/06/2020];28(5):607-10. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/29731453
González OZ, Egüez MJ, Fusté JC, Reyes ME, Borges LJ, González OL. Caracterización clínico-epidemiológica de pacientes con artritis reumatoide: características tomográficas y evolución. Rev. Finlay. 2015 [Acceso 21/06/2020];5(4):264-74. Disponible en: http://scielo.sld.cu/pdf/rf/v5n4/rf06405.pdf
Rachapalli SM, Williams R, Walsh DA, Young A, Kiely PD, Choy EH. First-line DMARD choice in early rheumatoid arthritis--do prognostic factors play a role? Rheumatology. 2018 [Acceso 21/06/2020];49(7):1267-71. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/20008093
Yu-Hsiang H, Ming-Shi C. IL- 20 in rheumatoid arthritis. Drug Discovery today. 2017 [Acceso 21/06/2020];22(6):960-4. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5913811/
Hyndman IJ. Rheumatoid arthritis: past, present and future approaches to treating the disease. Int J Rheum Dis. 2017;20(4):417-419. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/26845360
Audo R, Daien C, Papon L, Lukas C, Vittecoq O, Hahne M, et al. Osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as prognostic factors in rheumatoid arthritis: results from the ESPOIR cohort. Arthritis Res Ther. 2015;17(1):1-8. Disponible: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4518710/
Malm K, Bergman S, Andersson M, Bremander A. Predictors of severe self-reported disability in RA in a long-term follow-up study. Disability and Rehabilitation. 2015;37(8):686-691.Disponible: https://pubmed.ncbi.nlm.nih.gov/25036855/
De cock D, Hyrich K. Malignancy and rheumatoid arthritis: Epidemiology, risk factors and management. Best Practice & Research Clinical Rheumatology. 2018 [Acceso 21/06/2020];32(6):869-86. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1521694219300464
Singh JA, Saag KG, Bridges Jr. L, Akl EA, Raveendhara RB, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. ARTHRITIS & RHEUMATOLOGY. 2016 [Acceso 21/06/2020];68(1):1-26. Disponible en: https://www.rheumatology.org/Portals/0/Files/ACR%202015%20RA%20Guideline.pdf
Dumusc A, So A. Complications and systemic manifestations of rheumatoid arthritis. Rev Med Suisse. 2014 [Acceso 21/06/2020];10(421):592-4. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/24701711
Ostergaard M, Møller-Bisgaard S. Rheumatoid arthritis: Is imaging needed to define remission in rheumatoid arthritis?. Nat Rev Rheumatol. 2014 [Acceso 21/06/2020];10(6):326-8. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/24752184
Pisetsky DS. Advances in the Treatment of Rheumatoid Arthritis: Costs and Challenges. N C Med J. 2017 [Acceso 21/06/2020];78(5):337-40. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/28963273
Hyndman IJ. Rheumatoid arthritis: past, present and future approaches to treating the disease. Int J Rheum Dis. 2017;20(4):417-419. Disponible en: https://pubmed.ncbi.nlm.nih.gov/26845360/
Downloads
Published
How to Cite
Issue
Section
License
Warning of rights of author
The authors that publish in this journal agree with the following terms:
The authors conserve the rights of author and concede to the journal the right of the first publication, fulfilling with the license Creative Commons Attribution License that allows to others share the work with recognition of the authorship of their articles, and the initial publication in this journal.
The authors can establish separately additional agreements for the no exclusive distribution of the version of the work published in the journal (for example, situate it in an institutional repository, in a personal blog or publish it partial or totally in a book), with a recognition of their initial publication in this journal.
To be able to send the manuscript or part of him passed three months of published, for his evaluation to other publishers, identifying it or not with the same title; whenever allusion is made to our journale and know it the new publisher.
The publishing committee of the Cuban Journal of Rheumatology authorizes to other publishers, to reproduce the articles published in our magazine, whenever it indicate the origin of the same.
The authors should send a document in Office Word application format through the electronic address of the magazine with a similar format to that we include next:
---------------------------------------------------------------------------------------------------------------------
Statement of authorship and cede of articles for the publication of the scientific work in the Cuban Journal of Rheumatology
Date:
Those who subscribe certify that are the authors of the work:
Of this form communicate the originality of our article clearing that the concepts and knowledges of other authors that have included in the text of the article, have been quoted properly in the bibliography.
We do proof besides that the article in question is original and has not been published, total neither partially, in another journal.
To be approved for his publication in the Cuban Journal of Rheumatology, do secession of the rights of publication to the same one through the method that realizes it usually.
In front of any catchword that exist by the article that send to evaluate, relieve of of the responsibility to the Cuban Journal of Rheumatology holding us responsible with all the difficulties that can berelated by any situation.
We include to continuation the name and the signature of all authors and collaborators of this article.
Name: Signature:
